Genetically Engineered Escherichia coli Nissle 1917 Synbiotics Reduce Metabolic Effects Induced by Chronic Consumption of Dietary Fructose
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
AIMS: To assess protective efficacy of genetically modified Escherichia coli Nissle 1917 (EcN) on metabolic effects induced by chronic consumption of dietary fructose. MATERIALS AND METHODS: EcN was genetically modified with fructose dehydrogenase (fdh) gene for conversion of fructose to 5-keto-D-fructose and mannitol-2-dehydrogenase (mtlK) gene for conversion to mannitol, a prebiotic. Charles foster rats weighing 150-200 g were fed with 20% fructose in drinking water for two months. Probiotic treatment of EcN (pqq), EcN (pqq-glf-mtlK), EcN (pqq-fdh) was given once per week 109 cells for two months. Furthermore, blood and liver parameters for oxidative stress, dyslipidemia and hyperglycemia were estimated. Fecal samples were collected to determine the production of short chain fatty acids and pyrroloquinoline quinone (PQQ) production. RESULTS: EcN (pqq-glf-mtlK), EcN (pqq-fdh) transformants were confirmed by restriction digestion and functionality was checked by PQQ estimation and HPLC analysis. There was significant increase in body weight, serum glucose, liver injury markers, lipid profile in serum and liver, and decrease in antioxidant enzyme activity in high-fructose-fed rats. However the rats treated with EcN (pqq-glf-mtlK) and EcN (pqq-fdh) showed significant reduction in lipid peroxidation along with increase in serum and hepatic antioxidant enzyme activities. Restoration of liver injury marker enzymes was also seen. Increase in short chain fatty acids (SCFA) demonstrated the prebiotic effects of mannitol and gluconic acid. CONCLUSIONS: Our study demonstrated the effectiveness of probiotic EcN producing PQQ and fructose metabolizing enzymes against the fructose induced hepatic steatosis suggesting that its potential for use in treating fructose induced metabolic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Another group has engineered EcN to express genes responsible for the conversion of fructose, a prevalent sugar in the Western diet that contributes to metabolic disorders and cardiovascular disease, to mannitol, a prebiotic that has been demonstrated to confer protection against metabolic syndrome38.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
A comprehensive review on metabolic syndrome
Kaur, J. (2014) · Cardiology Research and Practice · doi:10.1155/2014/943162 · Cited by 1,889
Retracted[30] Microsomal lipid peroxidation
Buege, J. A., & Aust, S. D. (1978) · Methods in Enzymology · doi:10.1016/s0076-6879(78)52032-6 · Cited by 13,343
MARKLUND, S., & MARKLUND, G. (1974) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1974.tb03714.x · Cited by 10,354
Improved method for the determination of blood glutathione.
Beutler, E., Duron, O., & KELLY, B. M. (1963) · PubMed · Cited by 7,025
A SPECTROPHOTOMETRIC METHOD FOR MEASURING THE BREAKDOWN OF HYDROGEN PEROXIDE BY CATALASE
Beers, R. F., & Sizer, I. W. (1952) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50881-x · Cited by 6,761
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
Metabolic Effects of Fructose and the Worldwide Increase in Obesity
Tappy, L., & Lê, K.-A. (2010) · Physiological Reviews · doi:10.1152/physrev.00019.2009 · Cited by 1,256
AMPK: An Emerging Drug Target for Diabetes and the Metabolic Syndrome
Zhang, B. B., Zhou, G., & Li, C. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.03.012 · Cited by 1,026
Targeting gut microbiota in obesity: effects of prebiotics and probiotics
Delzenne, N. M., Neyrinck, A. M., Bäckhed, F., & Cani, P. D. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.126 · Cited by 779
Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase
Hardie, D. G., & Pan, D. A. (2002) · Biochemical Society Transactions · doi:10.1042/bst0301064 · Cited by 559
Research works printed but not linked: 1
- Sambrook J, Maccallum P, Russel D. Molecular cloning: A laboratory manual, Cold Springs Harbor Press, NY ISBN 0-87969-577-3: 2344; 2001.
Cited by
Isabella, V. M., Ha, B. N., Castillo, M. J., Lubkowicz, D. J., Rowe, S. E., Millet, Y. A., Anderson, C. L., Li, N., Fisher, A. B., West, K. A., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4222 · Cited by 605
Developing a new class of engineered live bacterial therapeutics to treat human diseases
Charbonneau, M. R., Isabella, V. M., Li, N., & Kurtz, C. B. (2020) · Nature Communications · doi:10.1038/s41467-020-15508-1 · Cited by 523
Abouelela, M. E., & Helmy, Y. A. (2024) · Microorganisms · doi:10.3390/microorganisms12030430 · Cited by 238
“[200]”
Designer probiotics for the prevention and treatment of human diseases
Chua, K. J., Kwok, W. C., Aggarwal, N., Sun, T., & Chang, M. W. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.04.011 · Cited by 137
才原一浩, Kamikubo, R., Ikemoto, K., Uchida, K., & Akagawa, M. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b01185 · Cited by 89
Gut microbiota and associated metabolites: key players in high-fat diet-induced chronic diseases
Du, W., Zou, Z., Ye, B., & Zhou, Y. Q. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2494703 · Cited by 91
“187 The engineered bacterium BsS-RS06551, which produces butyric acid, was developed using Bacillus subtilis as the cellular chassis.”
Synthetic Biology Approaches in the Development of Engineered Therapeutic Microbes
Kang, M., Choe, D., Kim, K., Cho, B., & Cho, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228744 · Cited by 64
“coli Nissle Fructose dehydrogenase, mannitol-2-dehydrogenase Hepatic steatosis Rats [52]”
BackgroundNative and Engineered Probiotics: Promising Agents against Related Systemic and Intestinal Diseases
Shen, H., Zhao, Z., Zhao, Z., Chen, Y., & Zhang, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020594 · Cited by 58
Production and Sensing of Butyrate in a Probiotic E. coli Strain
Bai, Y., & Mansell, T. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103615 · Cited by 47
“While most probiotic research has focused on the administration of microbes found in nature, some probiotics have been engineered to execute specific therapeutic activities, including delivery of antitumor drugs and insulin for cancer therapy and diabetes [20–22], secretion of antimicrobial peptides [23] and signaling…”
BackgroundWu, H., Chen, J., Guo, S., Deng, J., Zhou, Z., Zhang, X., Qi, T., Yu, F., & Yang, Q. L. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2500099 · Cited by 45
“217 These studies suggest that engineered bacteria can exert biological effects in the gut by synthesizing specific bioactive molecules.”
Living Therapeutics: The Next Frontier of Precision Medicine
Kelly, V. W., Liang, B. K., & Sirk, S. J. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.0c00444 · Cited by 30
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. Ø., & Sommer, M. O. A. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-05108-9 · Cited by 29
“coli Nissle 1917 has been used for many years in clinical settings and could prove to be a good chassis for advanced microbiome therapeutics in the future [11, 50, 56, 57, 58, 59, 60, 61].”
MethodA molecular toolkit for heterologous protein secretion across Bacteroides species
Yeh, Y.-H., Kelly, V. W., Pour, R. R., & Sirk, S. J. (2024) · Nature Communications · doi:10.1038/s41467-024-53845-7 · Cited by 26
Escherichia coli - Old and New Insights
Erjavec, M. S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95203 · Cited by 25
Chaudhari, A., Raghuvanshi, R., & Kumar, G. N. (2017) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-017-8207-7 · Cited by 18
“Enzymatic assays superoxide dismutase (SOD), catalase (CAT), lipid peroxidation, and reduced glutathione (GSH) were performed as described in Somabhai et al. (2016).”
BackgroundMethodInfluentialSelf-citationBacteria in the ageing gut: did the taming of fire promote a long human lifespan?
Danchin, A. (2018) · Environmental Microbiology · doi:10.1111/1462-2920.14255 · Cited by 16
Chiang, C., Chao, Y., Ali, A., Day, C. H., Ho, T., Wang, P., Lin, S., Padma, V. V., Kuo, W., & Huang, C. (2021) · Beneficial Microbes · doi:10.3920/bm2020.0094 · Cited by 16
Expectations for employing Escherichia coli Nissle 1917 in food science and nutrition
Hu, M., Zhang, T., Miao, M., Li, K., Luan, Q., & Sun, G. (2024) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2301416 · Cited by 14
“Under anaerobic conditions, EcN can produce beneficial metabolites, such as short-chain fatty acids, which can improve human health and protect against disease (Somabhai, Raghuvanshi, and Nareshkumar 2016; Sonnenborn and Schulze 2009).”
Jain, S., Shukla, A. K., DEEPIKA, D., Panwar, S., Kumari, A., Yadav, A. K., & Kumar, A. (2024) · Food Bioengineering · doi:10.1002/fbe2.12098 · Cited by 11
Meta-analysis of the effects of probiotics on hyperlipidemia
Yao, Y., Hong, Q., Ding, S., Cui, J., Li, W., Zhang, J., Sun, Y., Yu, Y., Yu, M., Mi, L., et al. (2024) · Current Research in Food Science · doi:10.1016/j.crfs.2024.100885 · Cited by 13
Jonscher, K. R., & Rucker, R. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814466-4.00013-6 · Cited by 10
Abubakar, D., Abdullahi, H., & Ibrahim, I. (2025) · Gut Microbes Reports · doi:10.1080/29933935.2025.2452471 · Cited by 9
“…that convert fruc-tose-a common sugar in Western diets linked to metabolic disorders and cardiovascular disease-into mannitol, a prebiotic that has been shown to protect against metabolic syndrome, 133 highlighting potential strategies to address both metabolic and thyroid-related dysfunctions.”
Designer Probiotics in Metabolic Disorders
Gupta, R. G., & Raghuwanshi, S. (2022) · Springer eBooks · doi:10.1007/978-981-16-8444-9_12 · Cited by 7
Potential of Escherichia coli Probiotics for Improved Health and Disease Management
Gattupalli, N., & Gattupalli, A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.100380 · Cited by 8
The engineered probiotics for the treatment of chronic diseases: A systematic review
Barati, M., Jabbari, M., Ghavidel, A. A., Nikmehr, P., Arzhang, P., Aynehchi, A., Babashahi, M., Mosharkesh, E., Roshanravan, N., Shabani, M., et al. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14343 · Cited by 4
Genetically Engineered Probiotics
Hag, S., & Poondla, N. (2020) · Springer eBooks · doi:10.1007/978-981-15-8214-1_14 · Cited by 6
Gut microbial strain improvement through genetic and metabolic engineering
Dey, P. (2026) · Gut Microbiome and Health · doi:10.1016/j.gmh.2026.100003 · Cited by 2
Arcidiacono, S. M., Spangler, J. R., Litteral, V., Doherty, L. A., Stamps, B. W., Walper, S. A., Goodson, M. S., & Soares, J. W. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00630 · Cited by 2
Zhang, J., Xu, J., Yin, J., Wang, X., Qi, Q., & Wang, Q. (2025) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00778 · Cited by 3
Microbiome Engineering for Metabolic Disorders
Aggarwal, N., Koh, E., Srivastava, S. K., Sieow, B. F., & Hwang, I. Y. (2022) · Wiley eBooks · doi:10.1002/9783527825462.ch2 · Cited by 2
Expanding the bio-capabilities of Lactococcus lactis through efficient genome modification
Rothstein, S. M. (2020) · Iowa State University Digital Repository (Iowa State University) · doi:10.31274/etd-20210114-128
Borg, R. E., Ozbakir, H. F., Xu, B., Li, E., Fang, X., Peng, H., Chen, I. A., & Mukherjee, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.07.495091
Effectiveness of Telemedicine Interventions on Mental Health Outcomes during Pandemics in Brazil
de Almeida, M. O. (2024) · Global Journal of Health Sciences · doi:10.47604/gjhs.2574
Novel Therapies: Pharmacological Approaches to Modulate the Gut Microbiome in Metabolic Syndrome
Gunjan, & Vidić, J. (2025) · Springer eBooks · doi:10.1007/978-981-96-6246-3_5
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558360
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558342
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558351
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558366
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. Ø., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558336
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558354
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558363
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558348
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558357
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558345
Hof, M. V. ‘., Mohite, O. S., Monk, J. M., Weber, T., Palsson, B. O., & Sommer, M. O. A. (2024) · Figshare · doi:10.6084/m9.figshare.26558339
Development strategies for engineered live biotherapeutic products for metabolic diseases
Yun, S., Choi, K.-S., Min, H., Jo, Y. K., & Jang, S. (2026) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2026.2653692 · Cited by 1
Metadata
- Authors
- Somabhai, C. A., Raghuvanshi, R., & Nareshkumar, G.
- Affiliations
- Maharaja Sayajirao University of Baroda (IN)
- Corresponding author
- Nareshkumar, G.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-10-19
- Volume
- 11
- Issue
- 10
- Pages
- e0164860
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5070853
- OpenAlex
- W2534649238
- Cited by
- 36
- References
- 39
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 7 · 2023: 1 · 2022: 6 · 2021: 3 · 2020: 6 · 2019: 1 · 2018: 2 · 2017: 3
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Department of Biotechnology, Ministry of Science and Technology
- Indian Council of Medical Research
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- Escherichia coli Nissle 1917, synbiotics, dietary fructose, fructose dehydrogenase, gluconic acid, pyrroloquinoline quinone, hepatic steatosis, metabolic syndrome, oxidative stress, dyslipidemia, hyperglycemia, short-chain fatty acids, genetically engineered probiotics
- MeSH terms
- Animals, Escherichia coli, Fructose, Genetic Engineering, Liver, Sugar Alcohol Dehydrogenases, Lipid Peroxidation, Oxidative Stress, Rats, Synbiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.